Difference between revisions of "Haloperidol"
From Psychiatrienet
| (4 intermediate revisions by one other user not shown) | |||
| Line 16: | Line 16: | ||
| avail = 60-70 | | avail = 60-70 | ||
| avail_ref = <ref name="informatorium">{{KNMP|haloperidol}}</ref> | | avail_ref = <ref name="informatorium">{{KNMP|haloperidol}}</ref> | ||
| − | | halflife = | + | | halflife = 17.5 |
| − | | halflife_ref = <ref name=" | + | | halflife_ref = <ref name="pts">{{pts|3791}}</ref><ref name="informatorium" /> |
| − | + | | administration = O,IM,IV | |
| − | |||
| − | | administration = O, IM, IV | ||
| dose = 0.25-15 | | dose = 0.25-15 | ||
| dose_ref = <ref name="informatorium" /> | | dose_ref = <ref name="informatorium" /> | ||
| DDD = 8 | | DDD = 8 | ||
| − | | DDD_ref = {{ | + | | DDD_ref = <ref>{{WHOCC|N05AD01}}</ref> |
| ctox = 20 | | ctox = 20 | ||
| ctox_ref = {{FTK-AP}} | | ctox_ref = {{FTK-AP}} | ||
| + | | cth = 5 | ||
| + | | cth_ref = <ref name="pts" /> | ||
| <includeonly> isswitch=1</includeonly> | | <includeonly> isswitch=1</includeonly> | ||
}} | }} | ||
Latest revision as of 11:58, 27 April 2010
| Haloperidol | |||||||||||||||||||
| Type | Antipsychotic | ||||||||||||||||||
| Group | Butyrophenones | ||||||||||||||||||
| links | |||||||||||||||||||
| ATC-code | N05AD01 | ||||||||||||||||||
| Medscape | Haloperidol | ||||||||||||||||||
| PubChem | 3559 | ||||||||||||||||||
| PubMed | Haloperidol | ||||||||||||||||||
| Drugs.com | haloperidol | ||||||||||||||||||
| Kompas (Dutch) | Haloperidol | ||||||||||||||||||
| Wikipedia | Haloperidol | ||||||||||||||||||
| |||||||||||||||||||
Haloperidol is a Antipsychotic in the group Butyrophenones.
- ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
- ↑ 2.0 2.1 2.2 KNMP; Informatorium Medicamentorum 2023; Monografie "haloperidol" (Dutch)
- ↑ 3.0 3.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
- ↑ 4.0 4.1 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
